Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 known ✓ | P12268 | 3/20 | 0.59 |
| ▸ | ROCK2 known ✓ | O75116 | 12/20 | 0.58 |
| ▸ | ROCK1 known ✓ | Q13464 | 3/20 | 0.58 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.57 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2162309 | 1.00 | IMPDH2 (0.59) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL12201759 | 0.98 | IMPDH2 (0.61) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL21430054 | 0.87 | IMPDH2 (0.62) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL20262924 | 0.85 | KDM4E (0.66) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL30176801 | 0.85 | KDM4E (0.66) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| Hydrochloric Acid SCHEMBL111600 | 0.85 | PRMT3 (0.62) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL19860095 | 0.85 | IMPDH2 (0.62) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL12201798 | 0.84 | PRMT3 (0.64) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL2162755 | 0.84 | NOTUM (0.62) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL19900450 | 0.81 | IMPDH2 (0.66) | IMPDH2PRMT3ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899714-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2020-06-11 | — | — | US | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
| US-9890123-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160280656-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2016-09-29 | — | — | US | disclosed |
| US-9365518-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150119419-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2015-04-30 | — | — | US | disclosed |
| US-8921392-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2118064-B1 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8455513-B2 | Kinase inhibitors; anticarcinogenic agents; obesity, glaucoma; N-(4-(3-(isoquinolin-6-ylamino)-3-oxopropyl)phenyl)-4-methoxybenzamide | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130137721-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8357699-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20110319390-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20100137364-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| EP-2118064-A2 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS, INC. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008086269-A2 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280656-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
| US-20130137721-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
| US-20100137364-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
| US-10472327-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
| US-10899714-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
| US-20150119419-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
| US-20110319390-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | IMPDH2 2131/4885ROCK2 246/4885ROCK1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.